Skip to main content
SpringerLink
Log in
Book cover

Cancer du testicule pp 63–74Cite as

Marqueurs tumoraux et tumeurs germinales du testicule

  • Chapter

  • 233 Accesses

Part of the book series: Monographies en urologie ((MONOGRAPHIES))

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Bosl GJ, Motzer J (1997) Testicular germ-cell cancer. New Eng J Med 337: 242–53

    PubMed  CAS  Google Scholar 

  2. International Germ Cell Cancer Collaboration Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603

    Google Scholar 

  3. Horwich A, Huddart R, Dearnaley D (1998) Markers and management of germ-cell tumours of the testes. Lancet 352: 1535–8

    Article  PubMed  CAS  Google Scholar 

  4. Eschwege P, Benoit G (2002) Tumeurs du testicule. Rev Prat 52: 1119–24

    PubMed  Google Scholar 

  5. Korhonen J, Afthan H, Ylostalo P et al. (1997) Disappearance of human chorionic gonadotropin and its α and β-subunits after term pregnancy. Clin Chem 43: 2155–63

    PubMed  CAS  Google Scholar 

  6. Bidart JM, Bellet D (1993) Human Chorionic Gonadotropin: Molecular forms, detection and clinical implications. Trends Endocrinol Metab 4: 285–91

    PubMed  CAS  Google Scholar 

  7. Bellet D, Lazar V, Bieche I et al. (1997) Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res 57: 516–23

    PubMed  CAS  Google Scholar 

  8. Berger P, Sturgeon C, Bidart JM et al. (2002) The ISOBM TD-7 workshop on hCG and related molecules. Tumor Biol 23: 1–38

    Article  CAS  Google Scholar 

  9. Ozturk M, Bellet D, Manil L et al. (1987) Physiological studies of human chorionic gonadotropin (hCG), αhCG, and βhCG as measured by specific monoclonal immunoradiometric assays. Endocrinology 120: 549–55

    PubMed  CAS  Google Scholar 

  10. Bellet D, Ozturk M, Bidart JM et al. (1986) Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. J Clin Endocrinol Metab 63: 1319–27

    Article  PubMed  CAS  Google Scholar 

  11. Afthan H, Haglund C, Dabek J et al. (1992) Concentrations of human choriogonadotropin, its β-subunit and the core fragment of the β-subunit in serum and urine of men and nonpregnant women. Clin Chem 38: 1981–7

    Google Scholar 

  12. Keller RH, Lyman S (1982) α-foetoprotein: biological and clinical potential. In: Rhodes BA, ed. Tumor imaging. New York: Masson Publishing: 41–52

    Google Scholar 

  13. Kamoto T, Satomura S, Yoshiki T et al. (2002) Lectin-reactive alpha-foetoprotein (AFPL3 %) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32: 472–6

    Article  PubMed  Google Scholar 

  14. Bellet D, Wands JR, Isselbacher KJ et al. (1984) Serum α-foetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci USA 8: 3869–73

    Google Scholar 

  15. Liu F, Fritscher HA, Trujillo JM et al. (1982) Serum lactate deshydrogenase isoenzyme 1 in patients with advanced testicular cancer. Am J Clin Path 78: 178–82

    PubMed  CAS  Google Scholar 

  16. Schmoll HJ, Beyer J, Pro J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–86

    PubMed  CAS  Google Scholar 

  17. Koshida K, Nishino A, Yamamoto H et al. (1991) The role of alkaline phosphatase isoenzymes as tumor markers for testicular germ cell tumors. J Urol 146: 47–60

    Google Scholar 

  18. Tandstad T, Klepp O (2003) Neuron-specific enolase in testicular cancer. Acta Oncol 42: 202–6

    Article  PubMed  Google Scholar 

  19. Treatment of testicular cancer (1985) Lancet: 258–9

    Google Scholar 

  20. Oliver RTD (1985) Factors contributing to delay in diagnosis of testicular tumours. Br Med J 290: 356

    Article  CAS  Google Scholar 

  21. Steele JPC, Oliver RTD (2002) Testicular cancer: perils of very late presentation. Lancet 359: 1632–3

    Article  PubMed  Google Scholar 

  22. Bellet D, Ranke A, Bressac B et al. (1989) Intérêt de l’alpha-foetoprotéine, de l’hormone chorionique gonadotrope et de sa sous-unité bêta libre pour le diagnostic, le pronostic et la surveillance des tumeurs germinales du testicule. In: Les marqueurs tumoraux, M Bolla et P Martin (Eds), Masson: 81–8

    Google Scholar 

  23. Hoshi S, Suzuki K, Ishidoya S et al. (2000) Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients. Int J Urol 7: 218–23

    Article  PubMed  CAS  Google Scholar 

  24. Mencel PJ, Motzer RJ, Mazumdar M et al. (1994) Advanced seminoma: treatment, results, survival, and prognosis factors in 142 patients. J Clin Oncol 12: 120–6

    PubMed  CAS  Google Scholar 

  25. Canil CM, Tannock IF (2002) Doctor’s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29: 286–93

    Article  PubMed  Google Scholar 

  26. Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-foetoprotein during therapy. J Clin Oncol 19: 2534–41

    PubMed  CAS  Google Scholar 

  27. Toner GC, Geller CK, Tan C et al. (1990) Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumors. Cancer Res 50: 5904–10

    PubMed  CAS  Google Scholar 

  28. Gerl A, Lamerz R, Clemm C et al. (1996) Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 2: 1565–70

    PubMed  CAS  Google Scholar 

  29. Picozzi VJ, Freiha FS, Hannigan JF et al. (1984) Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germcell carcinoma. Ann Intern Med 100: 183–6

    PubMed  Google Scholar 

  30. Horwich A, Peckham MJ (1986) Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 70: 1329–31

    PubMed  CAS  Google Scholar 

  31. Vogelzang NJ, Lange PH, Goldman A et al. (1982) Acute changes of α-foetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42: 4855–61

    PubMed  CAS  Google Scholar 

  32. Horwich A, Peckham MJ (1984) Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol 20: 1463–70

    Article  PubMed  CAS  Google Scholar 

  33. Droz JP, Kramar A, Nichols CR et al. (1995) Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognosis groups. Proc Am Soc Clin Oncol 12: 229 (abstr 704)

    Google Scholar 

  34. Murphy BA, Motzer RJ, Mazumdar M et al. (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73: 2520–6

    PubMed  CAS  Google Scholar 

  35. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48: 1151–9

    PubMed  CAS  Google Scholar 

  36. Morris MJ, Bosl GJ (2000) Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 163: 796–801

    PubMed  CAS  Google Scholar 

  37. Coppacks S, Newlands ES, Dent J et al. (1983) Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer 48: 335–40

    Google Scholar 

  38. Grem JL, Trump DL (1986) Reversible increase in serum α-foetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol 4: 41–5

    PubMed  CAS  Google Scholar 

  39. Pandha HS, Wasan HS, Harrington K et al. (1995) Lesson of the week: failure of normalisation of (alpha) foetoprotein concentration after successful treatment of teratoma. BMJ 311: 434–5

    PubMed  CAS  Google Scholar 

  40. Flechon A, Droz JP (2001) Hereditary persistence of α-foetoprotein in testis disease. J Urol 165: 2004

    PubMed  CAS  Google Scholar 

  41. Braunstein GD (2002) False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol 187: 217–24

    Article  PubMed  CAS  Google Scholar 

  42. Mills JN, Nguyen TT, Williams RD (2001) Falsely increased β-human chorionic gonadotropin with a testicular epidermoid cyst. 166: 2314

    CAS  Google Scholar 

  43. Bulger KN, Hesketh PJ, Babayan RK (1989) Discordant human chorionic gonadotropin results giving rise to inappropriate therapy in a case of testicular cancer. J Urol 142: 1574–5

    PubMed  CAS  Google Scholar 

  44. Kricka LJ (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45: 942–56

    PubMed  CAS  Google Scholar 

  45. Mazumdar M, Bacik J, Tickoo SK et al. (2003) Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-foetoprotein, and human chorionic gonadotropin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. J Clin Oncol 21: 2679–88

    Article  PubMed  CAS  Google Scholar 

  46. Brachmann AA, Beyer J, Jager R et al. (2003) Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14: 1525–9

    PubMed  Google Scholar 

  47. Aubry F, Satie AP, Rioux-Leclercq N et al. (2001) MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92: 2778–85

    PubMed  CAS  Google Scholar 

  48. Hechelhammer L, Storkel S, Odermatt B et al. (2003) Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch 443: 28–31

    Article  PubMed  CAS  Google Scholar 

  49. Mandoky L, Geczi L, Bodrogi I et al. (2003) Expression of HER-2/neu in testicular tumors. Anticancer Res 23: 3447–51

    PubMed  CAS  Google Scholar 

  50. Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de biologie du Pr Bellet, Institut Gustave-Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex

    D. Bellet

  2. Institut Gustave Roussy, 39, rue Camille Desmoulins, 94809, Villejuif Cedex

    F. Troalen

Authors
  1. D. Bellet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Troalen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Bellet, D., Troalen, F. (2006). Marqueurs tumoraux et tumeurs germinales du testicule. In: Cancer du testicule. Monographies en urologie. Springer, Paris. https://doi.org/10.1007/2-287-31232-3_6

Download citation

  • DOI: https://doi.org/10.1007/2-287-31232-3_6

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-21243-7

  • Online ISBN: 978-2-287-31232-8

Publish with us

Policies and ethics

Search

Navigation